Related Experiment Video
Updated: Dec 7, 2025

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
Published on: November 26, 2018
Emergence of overt myeloma in a patient with chronic lymphocytic leukemia on ibrutinib therapy
Ayad M Al-Katib1, Hussein Gaith1, Dahlia Sano2
1Lymphoma Research Laboratory Department of Internal Medicine Wayne State University School of Medicine (WSU SOM) Detroit MI USA.
Abstract:
Ibrutinib is approved for chronic lymphocytic leukemia (CLL). However, its role in the treatment of multiple myeloma (MM) is not clear and is under investigation. We report a case of CLL that developed MM while on therapy with ibrutinib indicating that this drug may not be active against MM.
Related Concept Videos
Treatment Resistant Cancers
Targeted Cancer Therapies
There are several types of targeted therapies against...
Primary Lymphoid Organs
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Differentiation of Common Myeloid Progenitor Cells

